检索结果-南通市图书馆

同方期刊数据库

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-yi Su Sun-Bin ling Qiao-Nan Shan Xu-Yong Wei Rui wang Chang-Ku Jia Li Zhuang Tian Shen Li-min Ding zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-ming Li Tai-Shi Fang Nan Jiang Kun zhang Zhao-Jie Su zhi-Hai Peng Ren Lang Tao Jiang Qiang He lin-Sen Ye Yang Yang Yu-Ting He Wen-zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye min Tian Jian-Hua Shi Bo wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-yin Yang Pu-Sen wang lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua zhang Xuan wang zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao zhang Ning-Qi Zhu Zheng-Xin wang Kang He Qiang Xia Shao-Hua song zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng song Ji-Zhou wang Zheng wang Jian Zhou Gang Chen ying-Peng Zhao Li Li Ze-min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi Deng Wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng Liu Li-hua wang Rong wang Nian-song wang Xiao-hong Cheng Li-qun He ping Luo Shi-ren Sun Ji-feng Sun Ai-ping yin Geng-ru Jiang Hong-yu Chen Wen-hu Liu Hong-li lin Meng Liang Lu Ma ming Chen Li-qun song Jian Chen Qing Zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li ying Li Hao zhang ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pmin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li Luo Yong-Heng Zhao Gang Zhao Li-Cai Deng Xiao-Wei Liu yi-Peng Jing Gang wang Hao-Tong zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-ping Li Zhong-Rui Bai Yue Wu Yan Cai Shu-Yun Cao zi-Huang Cao Jeffrey L.Carlin Hai-Yuan Chen Jian-Jun Chen Kun-Xin Chen Li Chen Xue-Lei Chen Xiao-Yan Chen ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui yi-Qiao Dong Bing Du Dong-Wei Fan Lei Feng Jian-Ning Fu Peng Gao Xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-Wen Han Bo-Liang He Jin-Liang Hou Yong-hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu zhi-ying Huo Lei Jia Fang-Hua Jiang Xiang Jiang zhi-Bo Jiang Ge Jin Xiao Kong Xu Kong Ya-Juan Lei Ai-Hua Li Chang-Hua Li Guang-Wei Li Hai-Ning Li Jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li Yan Li yin-Bi Li Ye-ping Li Yuan Liang Chien-Cheng lin Chao Liu Gen-Rong Liu Guan-Qun Liu zhi-Gang Liu Wen-zhi Lu Yu Luo yin-Dun mao Heidi Newberg Ji-Jun Ni Zhao-Xiang Qi Yong-Jun Qi Shi-yin Shen Huo-ming Shi Jing song yi-Han song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan wang Da-Qi wang Feng-Fei wang Guo-min wang Hai wang Hong-Chi wang Jian wang Jia-Ning wang Jian-ling wang Jian-ping wang Jun-Xian wang Lei wang Meng-Xin wang Shou-Guan wang Shu-Qing wang Xia wang Ya-Nan wang You wang Yue-Fei wang You-Fen wang Peng Wei ming-zhi Wei Hong Wu Ke-Fei Wu Xue-Bing Wu Yu-Zhong Wu Xiao-Zheng Xing ling-Zhe Xu Xin-Qi Xu Yan Xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang hui-Qin Yang ming Yang Zheng-Qiu Yao Yong Yu hui Yuan Hai-Bo Yuan Hai-Long Yuan Wei-min Yuan Chao Zhai En-Peng zhang Hua-Wei zhang Jian-Nan zhang Li-pin zhang Wei zhang Yong zhang Yan-Xia zhang Zheng-Chao zhang ming Zhao Fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Long-term analysis of clear nights using satellite data considering astronomical sites in western China

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 96-108页

作者： zi-Huang Cao Li-Yong Liu Yong-Heng Zhao Lu Feng Hugh RAJones Huang Shen Jin-Xin Hao Yan-Jie Xue Yong-Qiang Yao Jing Xu Ali Esamdin Zhao-Xiang Qi Jian-Rong Shi Jian Li Yuan Tian Zheng wang Tai-Sheng Yan Xia wang Jian-ping Xiong Si-Cheng Yu Jun-Bo zhang zhi-Xia Shen Yun-ying Jiang Jia yin Guang-Xin Pu Peng Wei Chun-Hai Bai Guo-Jie Feng Lu Ma Teng-Fei song Jian-Feng wang Jian-Feng Tian Xian-Qun Zeng zhi-Gang Hou Shi-Long Liao zhi-song Cao Dong-Wei Fan Yun-Fei Xu Chang-Hua Li yi-Han Tao National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Centre for Astrophysics University of HertfordshireHatfieldUK School of Journalism.Communication University of China Beijing 100024China Xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China Yunnan Observatories Chinese Academy of SciencesKunming 650216China

A large ground-based optical/infrared telescope is being planned for a world-class astronomical site in *** cloud-free night percentage is the primary meteorological consideration for evaluating candidate *** data from GMS and NOAA satellites and the MODIS instrument were utilized in this research,covering the period from 1996 to *** data analysis benefits from overlapping results from different independent teams as well as a uniform analysis of selected sites using GMS+NOAA *** significant ground-based monitoring is needed to validate these findings,we identify three different geographical regions with a high percentage of cloud-free conditions(~83%on average),which is slightly lower than at Mauna Kea and Cerro Armazones(~85%on average)and were chosen for the large international projects TMT and ELT *** study finds evidence that cloud distributions and the seasonal changes affected by the prevailing westerly winds and summer monsoons reduce the cloud cover in areas influenced by the *** is consistent with the expectations from climate change models and is suggestive that most of the identified sites will have reduced cloud cover in the future.

关键词： methods statistical-site testing-atmospheric effects-MODIS

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： ying-hui Jin Qing-Yuan Zhan zhi-Yong Peng Xue-Qun Ren Xun-Tao yin lin Cai Yu-Feng Yuan Ji-Rong Yue Xiao-Chun zhang Qi-Wen Yang Jianguang Ji Jian Xia yi-Rong Li Fu-Xiang Zhou Ya-Dong Gao Zhui Yu Feng Xu ming-Li Tu Li-ming Tan min Yang Fang Chen Xiao-Ju zhang Mei Zeng Yu Zhu Xin-Can Liu Jian Yang Dong-Chi Zhao Yu-Feng Ding Ning Hou Fu-Bing wang Hao Chen Yong-Gang zhang Wei Li Wen Chen Yue-Xian Shi Xiu-zhi Yang Xue-Jun wang Yan-Jun Zhong ming-Juan Zhao Bing-hui Li lin-Lu Ma Hao zi Na wang Yun-Yun wang Shao-Fu Yu Lu-Yao Li Qiao Huang Hong Weng Xiang-ying Ren Li-Sha Luo Man-Ru Fan Di Huang Hong-Yang Xue lin-Xin Yu Jin-ping Gao Tong Deng Xian-Tao Zeng Hong-Jun Li Zhen-Shun Cheng Xiao-Mei Yao Xing-Huan wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

Timing analysis of the black hole candidate EXO 1846–031 with Insight-HXMT monitoring

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2021年第3期21卷 193-204页

作者： He-Xin Liu Yue Huang Guang-Cheng Xiao Qing-Cui Bu Jin-Lu Qu Shu zhang Shuang-Nan zhang Shu-Mei Jia Fang-Jun Lu Xiang Ma Lian Tao Wei zhang Li Chen Li-ming song Ti-Pei Li Yu-Peng Xu Xue-Lei Cao Yong Chen Cong-Zhan Liu Ce Cai zhi Chang Gang Chen Tian-Xiang Chen yi-Bao Chen Yu-Peng Chen Wei Cui Wei-Wei Cui Jing-Kang Deng Yong-Wei Dong Yuan-Yuan Du min-Xue Fu Guan-Hua Gao He Gao min Gao ming-Yu Ge Yu-Dong Gu Ju Guan Cheng-Cheng Guo Da-Wei Han Jia Huo Lu-Hua Jiang Wei-Chun Jiang Jing Jin Yong-Jie Jin ling-Da Kong Bing Li Cheng-Kui Li Gang Li mao-Shun Li Wei Li Xian Li Xiao-Bo Li Xu-Fang Li Yang-Guo Li Zheng-Wei Li Xiao-Hua Liang Jing-Yuan Liao Bai-Sheng Liu Guo-Qing Liu Hong-Wei Liu Xiao-Jing Liu yi-Nong Liu Bo Lu Xue-Feng Lu Qi Luo Tao Luo Bin Meng yi Nang Jian-yin Nie Ge Ou Na Sai Ren-Cheng Shang Xin-ying song Liang Sun ying Tan You-Li Tuo Chen wang Guo-Feng wang Juan wang ling-Jun wang Weng-Shuai wang Yu-Sa wang Xiang-Yang Wen Bai-Yang Wu Bo-Bing Wu Mei Wu Shuo Xiao Shao-lin Xiong He Xu Jia-Wei Yang Sheng Yang Yan-Ji Yang yi-Jung Yang Qi-Bin yi Qian-Qing yin Yuan You Ai-Mei zhang Cheng-Mo zhang Fan zhang Hong-Mei zhang Juan zhang Tong zhang Wan-Chang zhang Wen-Zhao zhang yi zhang yi-Fei zhang Yong-Jie zhang Yuan-Hang zhang Yue zhang Zhao zhang zhi zhang zi-Liang zhang Hai-Sheng Zhao Xiao-Fan Zhao Shi-Jie Zheng Yao-Guang Zheng Deng-Ke Zhou Jian-Feng Zhou Yu-Xuan Zhu Ren-lin Zhuang Yue Zhu Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China University of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Institut fur Astronomie und Astrophysik Kepler Center for Astro and Particle PhysicsEberhard Karls Universität72076 TubingenGermany Department of Astronomy Beijing Normal UniversityBeijing 100088China Department of Astronomy Tsinghua UniversityBeijing 100084China Department of Physics Tsinghua UniversityBeijing 100084China Department of Engineering Physics Tsinghua UniversityBeijing 100084China Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China College of Physics Sciences&Technology Hebei UniversityBaoding 071002Hebei ProvinceChina

We present the observational results from a detailed timing analysis of the black hole candidate EXO 1846-031 during its outburst in 2019 with the observations of Insight-HXMT,NICER and *** outburst can be classified roughly into four different ***-C quasi-periodic oscillations(QPOs)observed by NICER(about 0.1-6 Hz)and Insight-HXMT(about 0.7-8 Hz)are also reported in this ***,we study various physical quantities related to QPO *** QPO rms-frequency relationship in the energy band 1-10 keV indicates that there is a turning pointing in frequency around2 Hz,which is similar to that of GRS 1915+105.A possible hypothesis for the relationship above may be related to the inclination of the source,which may require a high inclination to explain *** relationships between QPO frequency and QPO rms,hardness,total fractional rms and count rate have also been found in other transient sources,which can indicate that the origin of type-C QPOs is non-thermal.

关键词： X-ray binaries black hole candidate QPO EXO 1846–031

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-Liang Li ming-Sheng Huang Wei-Zhu Yang Guo-Wen yin Bin-Yan Zhong Jun-hui Sun zhi-Cheng Jin Jian-Jian Chen Nai-Jian Ge Wen-Bin Ding Wen-hui Li Jin-Hua Huang Wei Mu Shan-zhi Gu Jia-ping Li hui Zhao Shu-Wei Wen Yan-ming Lei Yu-Sheng song Chun-wang Yuan Wei-Dong wang ming Huang Wei Zhao Jian-Bing Wu song wang Xu Zhu Jian-Jun Han Wei-Xin Ren Zai-ming Lu Wen-Ge Xing Yong Fan Hai-Lan lin zi-Shu zhang Guo-hui Xu Wen-Hao Hu Qiang Tu Hong-ying Su Chuan-Sheng Zheng Yong Chen Xu-Ya Zhao Zhu-Ting Fang Qi wang Jin-Wei Zhao Ai-Bing Xu Jian Xu Qing-Hua Wu Huan-zhang Niu Jian wang Feng Dai Dui-ping Feng Qing-Dong Li Rong-Shu Shi Jia-Rui Li Guang Yang Hai-Bin Shi Jian-song Ji Yu-E Liu Zheng Cai Po Yang Yang Zhao Xiao-Li Zhu Li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Ptients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

凹叶厚朴离体培养初探

中南林业科技大学学报 2011年第7期31卷 179-182页

作者：宋荣马英姿张慧王志毅中南林业科技大学生命科学与技术学院湖南长沙410004

为了建立优质凹叶厚朴的离体快繁再生体系,分别对凹叶厚朴茎段外植体的消毒条件、腋芽诱导培养两个方面进行了初步研究,结果表明:最佳消毒条件为70%C2H5OH处理60 s,HgCl2处理12 min;最佳腋芽诱导配方为B5+NAA 0.05 mg.L-1+6-BA 1.0 mg.L... 详细信息

为了建立优质凹叶厚朴的离体快繁再生体系,分别对凹叶厚朴茎段外植体的消毒条件、腋芽诱导培养两个方面进行了初步研究,结果表明:最佳消毒条件为70%C2H5OH处理60 s,HgCl2处理12 min;最佳腋芽诱导配方为B5+NAA 0.05 mg.L-1+6-BA 1.0 mg.L-1,腋芽诱导率可达55%。

关键词：凹叶厚朴正交设计腋芽诱导消毒条件

在线全文

学校读者我要写书评

暂无评论

凹叶厚朴离体胚培养的研究

中南林业科技大学学报 2012年第5期32卷 50-53页

作者：王志毅马英姿王晓明宋荣张慧中南林业科技大学生命科学与技术学院湖南长沙410004 湖南省林业科学院湖南长沙410004

为了满足市场的资源需求,建立优质凹叶厚朴离体再生体系,为凹叶厚朴工厂化生产提供理论依据,以优质凹叶厚朴离体胚为外植体,以B5为基本培养基,6-BA、NAA、消毒时间为因素,采用L9(33)正交设计,进行无菌苗培养优化试验。结果表明:最佳消... 详细信息

为了满足市场的资源需求,建立优质凹叶厚朴离体再生体系,为凹叶厚朴工厂化生产提供理论依据,以优质凹叶厚朴离体胚为外植体,以B5为基本培养基,6-BA、NAA、消毒时间为因素,采用L9(33)正交设计,进行无菌苗培养优化试验。结果表明:最佳消毒方法为0.1%升汞浸泡8 min,污染率为12.6%,外植体生长良好;最佳组合为B5+6-BA 0.5 mg/L+NAA 0.1 mg/L+消毒时间8 min,发芽率高达87%。

关键词：凹叶厚朴正交设计再生体系发芽率